ERBB2 and non-small cell lung carcinoma: T-DM1 did not exhibit a significant therapeutic effect in patients with HER2-positive NSCLC, contrary to the conclusions drawn from cellular and animal studies and in contrast to gastric cancer, which showed similar results.